Sonnet BioTherapeutics Advances Solid Tumor Trial
Company Announcements

Sonnet BioTherapeutics Advances Solid Tumor Trial

An announcement from Sonnet BioTherapeutics Holdings ( (SONN) ) is now available.

Sonnet BioTherapeutics has successfully finished enrolling participants for its Phase 1 SB101 clinical trial of SON-1010, targeting advanced solid tumors, with topline data expected in Q4 2024. SON-1010, leveraging the company’s proprietary FHAB® platform, aims to enhance the drug’s half-life and tumor targeting by binding to native albumin in the serum. The study, which has reported no significant adverse effects, is designed to determine the maximum tolerated dose of SON-1010 and has shown promising safety and tolerability results, including controlled cytokine response and no instances of cytokine release syndrome, signaling a potential breakthrough in turning ‘cold’ tumors ‘hot’.

For detailed information about SONN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlySonnet BioTherapeutics files to sell common stock, warrants, no amount given
TipRanks Auto-Generated NewsdeskSonnet BioTherapeutics Maintains Nasdaq Listing Compliance
TheFlySonnet BioTherapeutics regains compliance with Nasdaq
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App